JP2023521030A5 - - Google Patents

Info

Publication number
JP2023521030A5
JP2023521030A5 JP2022560218A JP2022560218A JP2023521030A5 JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5 JP 2022560218 A JP2022560218 A JP 2022560218A JP 2022560218 A JP2022560218 A JP 2022560218A JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5
Authority
JP
Japan
Application number
JP2022560218A
Other languages
Japanese (ja)
Other versions
JP2023521030A (ja
JPWO2021207054A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025732 external-priority patent/WO2021207054A1/en
Publication of JP2023521030A publication Critical patent/JP2023521030A/ja
Publication of JPWO2021207054A5 publication Critical patent/JPWO2021207054A5/ja
Publication of JP2023521030A5 publication Critical patent/JP2023521030A5/ja
Pending legal-status Critical Current

Links

JP2022560218A 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 Pending JP2023521030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (3)

Publication Number Publication Date
JP2023521030A JP2023521030A (ja) 2023-05-23
JPWO2021207054A5 JPWO2021207054A5 (https=) 2024-04-15
JP2023521030A5 true JP2023521030A5 (https=) 2024-04-15

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560218A Pending JP2023521030A (ja) 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法

Country Status (6)

Country Link
US (2) US12213966B2 (https=)
EP (1) EP4132521A1 (https=)
JP (1) JP2023521030A (https=)
CN (1) CN115335049A (https=)
CA (1) CA3174413A1 (https=)
WO (1) WO2021207054A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
WO2023150093A1 (en) * 2022-02-01 2023-08-10 Medicinova, Inc. Ibudilast for use in the treatment of post-covid conditions
JP2025523822A (ja) * 2022-07-13 2025-07-25 メディシノバ・インコーポレイテッド イブジラストの注射用製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Similar Documents

Publication Publication Date Title
JP2023521030A5 (https=)
BR112023016292A2 (https=)
CN305536504S (https=)
CN305535666S (https=)
CN305537021S (https=)
CN305537001S (https=)
CN305536956S (https=)
CN305536192S (https=)
CN305535404S (https=)
CN305535181S (https=)
CN305533858S (https=)
CN305533187S (https=)
CN305531975S (https=)
CN305531406S (https=)
CN305530841S (https=)
CN305530433S (https=)
CN305529937S (https=)
CN305529324S (https=)
CN305528895S (https=)
CN305528631S (https=)
CN305528537S (https=)
CN305528517S (https=)
CN305527701S (https=)
CN306177073S (https=)
CN305917387S (https=)